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Objectives 
• Increase understanding of the general 
characteristics of non-CF Bronchiectasis 
• Develop an approach to work-up & 
management 
• Categorize & review heterogeneous causes 
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Bronchiectasis 
• Irreversible abnormal dilation of bronchial tree 
• Inflamed, collapsible airways 
• Bacterial Colonization (S. aureus, H. influenzae, P. 
aeruginosa)  
• Chronic productive cough (wet vs. dry) 
– Collected sputum→3 layers (foam, clear, purulent) 
– cough 90%, sputum 76%, dyspnea 72%, hemoptysis 56% 
• Exam: rales 70%, rhonchi 44%, wheeze 34%. 
• Obstructive physiology 
– Low FEV1, FVC preserved 
– Decreased DLCO 
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US Prevalence of Non-CF Bronchiectasis 
 Total Prevalence: ~52/100,000 
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Prevalence may be increasing 
Sl F>M predominance 
Useless Morphology Classification 
• Bronchiectasis can be: 
– Focal (lobe/segment) 
– Diffuse  
• Cylindrical: creates tram 
track lines 
• Varicose: beaded 
bronchi. 
• Cystic: occ large cysts 
imitate cavity or give 
grape cluster pattern 
Vicious Cycle Hypothesis 
• Microbial colonization initiates & perpetuates 
airway inflammation 
• PMNs infiltrate lungs & cause structural 
airway damage 
• Impaired mucociliary clearance. 
• Optimal for bacterial growth & certain spp. 
Selection (eg, S aureus, H flu, P aeruginosa) 

Bronchiectasis Differential Diagnosis 
• Idiopathic (50→10%...) 
• Airway obstruction 
• Primary Ciliary Dyskinesia Syndrome (PCD) 
• Immunodeficiency (Ig Def, CLL/Rx, GVHD, HIV) 
• Post-infectious 
• Diffuse Panbronchiolitis 
• Inflammatory Disease 
• Alpha-1-Antitrypsin Syndrome 
• Cystic Fibrosis 
Airway Obstruction 
• Foreign Body Aspiration 
– Lower lobes, posterior segment upper lobe 
• Obstruction broncholith, slow 
growing/B9 tumor 
• Lymph nodes enlargement 
– Middle Lobe Syndrome 
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Primary Ciliary Dyskinesia (PCD) 
• Incidence ~ 1/15000 – 1/60000 
• Autosomal recessive (some DNAH11) 
• Classic triad 
– Bronchiectasis 
– Sinusitis 
– Variable male sterility 
• Situs inversus (50%) = Kartagener’s 
• Classic ultrastructure defect… 
Nasal NO for PCD Diagnosis 
• Proper SOP, nNO <77: Sensitivity 98%, Spec 99% 
• 6 other centers: Identified correctly 70 out of 71 PCD 
• Technology more user friendly 
• nNO for screening then confirm by EM, in vitro/vivo assess 
Leigh et al. Ann ATS 2013;10:574-81 
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Immunodeficiency 
• Hypogammaglobinemia presents in children 
– Recurrent sinopulmonary infections (middle ear) 
– Can be acquired in elderly 
– Measure IgA, IgG, and IgG subclasses 
– Measure response to protein, polysaccharide vaccine 
– NB: D/t dysregulated T-cell function lung/LN bx may show 
granuloma → misDx sarcoid/TB/NTM 
– Treatment: IVIG infusion q mo. 
• Heme-Malig: CLL, post rituximab, GVHD  
• AIDS associated bronchiectasis (recurrent infection) 
• Jobs Syndrome 
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Post-Infectious 
• Viral, Mycoplasma 
• TB 
• Pertussis 
• Nontuberculous mycobacteria & Nodular 
Bronchiectasis 
• Aspergillus 
• Severe/recurrent bacterial pneumonia 
– Post-op. nosocomial pneumonia 
– Associated with kyphoscoliosis 
 
What do you know about 
Nodular/Bronchiectasis Form of 
MAC Lung Infection? 
What about Rapid Growers?  
NTM Lung Infection a/w Pre-existing 
Bronchiectasis or CF? 
Fascinating Stuff???… 
Post-Infectious 
• Viral, Mycoplasma 
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• Pertussis 
• NTM and nodular bronchiectasis 
• Aspergillus 
• Severe/recurrent bacterial pneumonia 
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Allergic Bronchopulmonary Aspergillosis 
(ABPA) 
1.  Asthma 
2.  Skin test reactivity to Aspergillus fumigatus 
3.  Serum precipitins to Aspergillus fumigatus 
4.  IgE elevation (>1000 ng/ml or >500 IU/ml) 
5.  Specific IgE (IgG) antibodies to Aspergillus fumigatus 
 
6.  Proximal Bronchiectasis 
7.  Pulmonary Infiltrates (eg. fleeting, upper lobes, mucoid 
impaction) 
8.  Eosinophilia with pulmonary infiltrates 
Note:   Positive sputum culture not essential for diagnosis 
  Allergic Bronchopulmonary Mycosis (other Aspergillus spp, 
  Candida, other fungi) 
Adapted from Patterson & Greenberger 
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• Airway obstruction 
• Dyskinetic Cilia Syndrome 
• Immunodeficiency (Agammaglobulinemia) 
• Post-infectious 
• Diffuse Panbronchiolitis 
• Inflammatory Disease 
• α-1 Antitrypsin Syndrome 
• Cystic Fibrosis 

Diffuse Panbronchiolitis (DPB) 
• Japanese, Korean, M:F 2:1, onset 20-80 y.o 
• Clinical characteristics 
– Chronic sinusitis 75%, precedes lung disease (yrs or decades) 
– Productive cough, dyspnea, wheezing, weight loss, clubbing 
uncommon 
– Sputum: H. influenzae, S. aureus, P. aeruginosa 
– Acquisition of Psa→poor survival (8%@  5 yr) 
– PFTs: obstructive, mixed obstructive/restrictive 
– Histopath: localized to resp bronch. 
transmural inflammation (lymphocytes, 
foamy macrophages) 
– No: exocrine dysfunction, ↑ sweat Cl, 
CFTR abnormality 
Survival Curves According to Year of Diagnosis 
Kudoh S. Curr Opin Pulm Med 1998 
Group A = 1970 - 1979, n= 190 
           B = 1980 - 1984, n= 221 
           C = 1985 - 1990, n= 87  WHY? 
DPB and Macrolide Rx 
• Serendipitous discovery 1982 
• Standard:  E-mycin 400-600 mg/day continuous 
• No significant change in bacterial flora &  
serum levels (1 µg/ml) don’t exceed MICs 
• Clinical factors improved 
– Randomized blinded trial (Yamamoto et al, 1991) 
• 3 mos E-mycin vs. placebo 
• Improved DOE, sputum volume, CRP, PFTs, CXR)  
– PFTs 
– P. aeruginosa infected group improves also 
– Mortality rates decreased 
• Other macrolides tested (clari-, roxi-, azithromycin) 
In vitro data: Macrolides modulate inflammatory response &  
                     Inhibit P. aeruginosa virulence factors (eg, biofilm) 
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Young’s Syndrome 
• Similar to CF 
• Sinusitis, bronchiectasis, azoospermia 
• Nl Sweat Cl, NPD 
• Nl pancreas function 
• No genetic link yet found 
• Infertile middle age males 
• Decreasingly found (toxic exposure 
births/prior era?) 
Inflammatory Diseases & 
Bronchiectasis 
• Sjogren’s Syndrome 
• Rheumatoid Arthritis 
• Ulcerative Colitis >> Crohn’s disease 
Alpha-1-Antitrypsin Deficiency 
• Radiographic: 
– Cystic bronchiectasis 10-20% 
– Emphysema co-exists or overshadowed 
– No other predisposing illness 
• Uncertain clinical correlation (sputum production) 
• No pathophysiologic association 
– All causes bronchiectasis: no increase in AAT alleles 
(Cuvilier et al: Chest 2000) 
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Differential Dx  
(Mnemonic: IA_SPICE) 
• Idiopathic 
• Airway Obstruction 
• Sjogren’s & other Inflammatory (RA, IBD) 
• Post-Infectious (TB, non-tuberculosous 
mhycobacteria, Aspergillus, Pertussis, NP, virus) 
• Immunodeficiency (Ig, AIDS) 
• CF & other genetic/congenital (Primary Ciliary 
Dyskinesia, Sequestration, α-1 Anti-trypsin) 
• Esoteric (Diffuse Panbronchiolitis, Yellow Nail Syn., 
Tracheobronchomegaly [Mounier-Kuhn], Cartilage 
deficiency [Williams-Campbell], Swyer James) 
How do you evaluate a 
patient for bronchiectasis? 
Evaluation for Bronchiectasis 
• History 
– Poorly resolving/recurrent pneumonia 
– Purulent sputum (quantify) 
– H/O of difficult asthma management 
– Family history/GI problems/infertility 
• Exam 
– nasal polyps 
– localized rales, wheezes, or rhonchi 
– clubbing 
Evaluation for Bronchiectasis 
Lab Data 
• Spirometry 
• Sputum Gram Stain & Culture (quantitative) 
– S. aureus, H. influenzae 
– P. aeruginosa (mucoid?) 
– AFB smear/culture (AM x3 Mail Back) 
• Consider: 
– Immunoglobulin electrophoresis & quantification of IgG subclasses; 
pre/post PVX/DT titers 
– Sweat Chloride, CF genetics (Ambry lab), NPD 
– RF, CCP, ANA, SSA, SSB antibodies  
– Exhaled nasal Nitric Oxide screen, then EM, genetics,  
– Asthma?, Eos?, Aspergillus skin test, IgE (ARUP ABPA panel) 
– Bronchoscopy for cultures (eg, elderly: NTM, other bacteria) 
• Radiology Evaluation 
– Chest x-ray & High Resolution Chest CT 
– Sinus CT 
What are the radiographic 
features of bronchiectasis? 
Radiography 
• Bonchograms (history of medicine) 
• CXR and High Resolution CT 
– Signet Ring   Engagement Ring 
– Tram Tracks  Railroad tracks 
 
Swollen airway wall 




• High resolution= 
Thin sections  










• Railroad tracks 
Bronchus Vessel 
Bronchus Vessel 
HRCT: Other Characteristics 
• Lack of tapering bronchi 
 
• Clusters = Grape-like appearance 
 
• Enlarged bronchi can appear cystic vs. 
Blebs of emphysema (thinner walls) 
Lack of Tapering Bronchi 
Grape-like Clusters 
Cystic Bronchi 
HRCT bronchiectasis Dx 
• Central→ABPA 
 
• Upper lobe → CF 
 
• Lobar → Post-infectious; obstructive (eg, LN, FB) 
 
• Correlation: # abnormal airways and severity 
Traction Bronchiectasis 
 
• Radiographic finding 
w/o clinical features of 
bronchiectasis 
• Pulmonary Fibrosis 
• Radiation injury 
How do you identify acute 
exacerbation of 
bronchiectasis? 
Sypmtoms of Acute Exacerbation 
of Bronchiectasis 
• Change in sputum production 
• Increased dyspnea 
• Increased cough 
• Increased wheezing 
• Malaise, fatigue, lethargy, decreased exercise 
tolerance 
• ± Fever (T>38) 
• Changes in chest exam 
• Reduced pulmonary function 
• Radiographic changes (subtle vs. new infiltrate) 
Adapted from Odonnell et al: Chest 1998 
How do you treat 
bronchiectasis? 
Rx Extrapolated from CF… 
• Antibiotics generally effective for chronic Rx 
– Suppress bacteria burden: ↓ bacteria = ↓ evil cytokines   
• Nebulized tob, gent, colistin effective, small trials 
• Nebulized aztreonam (Cayston) not effective 
– Eradication Rx for P aeruginosa likely effective 
– Cycling antibiotics: no supportive data, but often done 
• Exacerbation: IV antibiotics aimed at predom spp 
…little supportive data 
• Pulmozyme trial…not good, maybe harmful 
• Anti-inflammatory Rx 
– Avoid long term steriods except ABPA 
– ICS weak data; ICS/LABA no supportive data (ex. Asthma too) 
– Macrolide randomized control trial data supportive 
Azithro MWF (EMBRACE, BAT trials) & E-mycin 250 bid (BLISS) 
Brodt et al. Eur Resp J 2014;44:382-93; Barker AF et al. Lancet Resp Med Aug 2014; O’Donnell AE et al Chest 1998 
Wong C et al. Lancet 2012;380:660-67; Altenburg J et al. JAMA 2013;309:1251-1259; Serisier JD et al. JAMA 2013;309:1260-67 
Bronchiectasis Treatment Overview 
• Manage/alter underlying cause 
• Antibiotics 
– Acute exacerbation, parenteral abx based on culture & susceptibilities 
– Preventive strategies-uncertain benefit 
• Cycling Abx (no real data to support) 
• Inhaled Abx (tobramycin [gent], colistin, not aztreonam) 
• 7% saline neb bid 
• Bronchodilators (widely used…no good data) 
• Chest physiotherapy (various modalities) & Aerobic exercise 
• Pulmozyme…No 
• ICS (minimal if any benefit) 
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